Satellite Bio

Satellite Bio is a biopharmaceutical and biotechnology startup founded in 2019 in the United States. The company's mission, as encapsulated in its slogan, is centered around "Tackling some of humankind’s most elusive diseases with Tissue Therapeutics, a new category of regenerative medicine." Satellite Bio has developed the groundbreaking SAT (Satellite Adaptive Tissues) platform, which can transform various cell types into bioengineered tissues named Satellites. These Satellites are integrated into the body to restore natural function, offering a comprehensive cellular response to repair or replace critical organ functions in patients with diseases arising from genetic and environmental factors. The technology has the potential to drive a pipeline of sophisticated cell-based therapeutic solutions that target a wide array of elusive diseases. Satellite Bio secured a significant investment of $82.47M in a Series A funding round on 07 March 2022. The investment was led by a consortium of prominent venture capital firms including Lightspeed Venture Partners, Polaris Partners, Alumni Ventures Blockchain Fund, aMoon, Catalio Capital Management, Section 32, and Waterman Ventures. The company's ambitious quest is to bring new hope to patients and families affected by challenging diseases, and their commitment to Tissue Therapeutics underscores their dedication to realizing the potential of regenerative medicine's compelling new frontier.